Business Information
The group's principal activity is to design, develop, manufacture, and market medical products for the treatment of urinary incontinence and vesicoureteral reflux. The group's main product is macroplastique(R) implants, an injectable, soft tissue bulking agent used to treat certain types of stress urinary incontinence ("Sui"). Sui refers to the involuntary loss of urine as a result of activities that increase intra-abdominal pressure. Macroplastique is also used to treat vesicoureteral reflux ("Vur") , a condition occurring mostly in children in which urine flows backward from the bladder into the kidney. In addition, the group's implantable bulking material is also sold for reconstructive and cosmetic plastic surgery applications under the trade name bioplastique(tm). The group's international operations are in the Netherlands, the United Kingdom and Canada. The group markets its products only outside the United States, primarily in Europe.
|
|
Name |
Title
|
Email
|
| Patrick Maxwell | Chmn. | N/A | | Mahedi Jiwani | CFO, VP, Treasurer | N/A | | Susan Holman | Sec., COO, VP - Operations, Regulatory Affairs | N/A | | Larry Heinemann | VP - Sales, Marketing | N/A | | Marc Herregraven | VP - Manufacturing | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 6,143 | (4,543) | | 2005 | 6,658 | (1,735) | | 2004 | 5,715 | (1,511)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
